Mesoblast Selects Medidata’s Cloud-based Clinical Research Platform to Accelerate Cutting-edge Stem Cell Research

  Mesoblast Selects Medidata’s Cloud-based Clinical Research Platform to
  Accelerate Cutting-edge Stem Cell Research

 Leading Researcher Streamlines Regenerative Medicine Trials with Medidata’s
 Data Capture and Management, Site Monitoring, Coding and Safety Applications

Business Wire

NEW YORK -- September 12, 2012

Medidata Solutions (NASDAQ: MDSO) continues to lead the market with its
cloud-based clinical development platform through a new customer commitment
from Mesoblast Limited, a world leader in developing biologic products for the
broad field of regenerative medicine. Mesoblast will implement Medidata
Rave^®, including Rave Safety Gateway and Rave Targeted SDV, and Medidata
Coder™ across its clinical studies to support the development of treatments
based on its proprietary adult stem cell technology.

Medidata’s platform is seen as a cost-efficient solution to improve
Mesoblast’s clinical trial efficiencies across multiple therapeutic areas, to
effectively monitor and control risks, and to streamline trial execution to
meet tight deadline goals.

Medidata Rave, a leading electronic data capture (EDC) and clinical data
management (CDM) solution, enables real-time visibility into clinical trial
data. The flexibility of Rave allows Mesoblast to proactively adjust a trial’s
data validation plan and management processes, and also apply learnings to
other studies in a timely fashion to improve trial quality and efficiency.

Mesoblast selected Rave for its superior user experience and comprehensive
functionality. The context-sensitive, on-screen help minimizes the dependence
on calling help desks and eliminates delays in entering and cleaning data.
Moreover, research sites’ familiarity with Rave will help Mesoblast to
expedite site initiation.

Further building out the clinical trial process, Mesoblast selected Rave
Targeted SDV to reduce site monitoring costs through a risk-based approach.
The implementation of Rave Safety Gateway and Medidata Coder will enable
Mesoblast to increase the efficiency of its safety reporting process.

  *“Mesoblast chose Medidata Solutions for our ability to drive improved
    efficiency and more effective decision making across their trials
    process,” said Tarek Sherif, CEO, Medidata Solutions. “We’re very excited
    that the Medidata Clinical Cloud is playing a key role in allowing
    Mesoblast to execute at the forefront of regenerative medicine research
    and adult stem cell technology.”

Connect with Medidata:

  *Read our blog, Geeks Talk Clinical
  *Tweet this: Mesoblast selects @Medidata #cloud based #clinical platform to
    accelerate development of adult stem cell technology http://bit.ly/S8Vjwt
  *Follow us on Twitter: @Medidata
  *Find us on LinkedIn

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical
development solutions that enhance the efficiency of customers’ clinical
trials. Medidata’s advanced platform lowers the total cost of clinical
development by optimizing clinical trials from concept to conclusion: from
study and protocol design, trial planning and budgeting, site negotiation,
clinical portal, trial management, randomization and trial supply management,
clinical data capture and management, safety events capture, medical coding to
business analytics. Our diverse life science customer base spans
biopharmaceutical companies, medical device and diagnostic companies, academic
and government institutions, CROs and other research organizations, and
includes more than 20 of the top 25 global pharmaceutical companies as well as
organizations of all sizes developing life-enhancing medical treatments and
diagnostics.

Contact:

Lois Paul and Partners
Susan McCarron, 617-986-5767
Susan_mccarron@lpp.com